Mangoceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.84	0.73	0.01	-
Revenue Growth (YoY)	670.43%	8083.16%	-	-
Cost of Revenue	0.32	0.3	0	-
Gross Profit	0.52	0.43	0	-
Selling, General & Admin	9.39	8.55	2	0.07
Research & Development	0.04	-	-	-
Other Operating Expenses	0.54	-	-	-
Operating Expenses	9.97	8.55	2	0.07
Operating Income	-9.45	-8.12	-1.99	-0.07
Interest Expense	-	-	-0.01	-0
Interest & Investment Income	0	-	-	-
Other Non Operating Income (Expenses)	0.43	-1.09	-	-
Pretax Income	-9.02	-9.21	-2	-0.07
Earnings From Continuing Operations	-9.02	-	-	-
Minority Interest in Earnings	0	-	-	-
Net Income	-9.02	-9.21	-2	-0.07
Net Income to Common	-9.02	-9.21	-2	-0.07
Shares Outstanding (Basic)	19	16	11	8
Shares Outstanding (Diluted)	19	16	11	8
Shares Change (YoY)	63.67%	49.22%	34.98%	-
EPS (Basic)	-0.47	-0.57	-0.19	-
EPS (Diluted)	-0.47	-0.57	-0.19	-
Free Cash Flow	-6.18	-7	-1.39	-0.07
Free Cash Flow Per Share	-0.33	-0.43	-0.13	-0.01
Gross Margin	61.75%	58.99%	54.26%	-
Operating Margin	-1118.44%	-1109.84%	-22279.70%	-
Free Cash Flow Margin	-731.50%	-957.07%	-15545.59%	-
EBITDA	-9.42	-8.09	-1.99	-
D&A For EBITDA	0.03	0.02	0	-
EBIT	-9.45	-8.12	-1.99	-0.07

Source: S&P Capital IQ. Standard template.